PaxMedica (PaxMedica) Scaled Net Operating Assets : -0.08 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PaxMedica's operating assets for the quarter that ended in Mar. 2024 was $1.27 Mil. PaxMedica's operating liabilities for the quarter that ended in Mar. 2024 was $1.70 Mil. PaxMedica's Total Assets for the quarter that ended in Dec. 2023 was $5.68 Mil. Therefore, PaxMedica's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.08.

PaxMedica Scaled Net Operating Assets Historical Data

The historical data trend for PaxMedica's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Scaled Net Operating Assets Chart

PaxMedica Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-13.67

-205.60

-9.39

-2.50

-0.60

PaxMedica Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.04	0.18	-0.02	-0.41	-0.08

Competitive Comparison of PaxMedica's Scaled Net Operating Assets

For the Biotechnology subindustry, PaxMedica's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PaxMedica's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PaxMedica's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where PaxMedica's Scaled Net Operating Assets falls into.

PaxMedica Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PaxMedica's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(0.969	-	2.295)	/	2.204
=	-0.60

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.68	-	4.711
=	0.969

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.295	-	0	-	0
=	2.295

PaxMedica's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(1.266	-	1.703)	/	5.68
=	-0.08

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2.893	-	1.627
=	1.266

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.703	-	0	-	0
=	1.703

PaxMedica Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of PaxMedica's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

PaxMedica (PaxMedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591

Website

https://www.paxmedica.com

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Executives

Zachary Rome	director, officer: Chief Operating Officer	C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby	director, officer: Executive Chairman	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman	director, officer: Chief Executive Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle	director	900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho	director	22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough	officer: Chief Medical Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc	10 percent owner	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon	officer: Chief Financial Officer	2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748